Beplate Amends Ownership Filing for United Health Products

TL;DR

Beplate filed a 13D/A for UECC, watch for ownership changes.

AI Summary

Douglas K. Beplate filed an amendment (No. 1) to Schedule 13D on December 3, 2024, for United Health Products, Inc. This filing indicates a change in beneficial ownership of the company's common stock. The specific details of the change in ownership, including the number of shares and percentage held, are not fully detailed in the provided text but are the subject of this amendment.

Why It Matters

This amendment signals a potential shift in control or significant stake changes for United Health Products, Inc., which could impact its stock price and strategic direction.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D often indicate significant changes in beneficial ownership, which can lead to increased volatility and uncertainty.

Key Players & Entities

• Douglas K. Beplate (person) — Filing person and authorized contact
• United Health Products, Inc. (company) — Subject company
• 91059D100 (other) — CUSIP Number for United Health Products, Inc. common stock
• 0001477932-24-007836 (other) — Accession Number for the filing

FAQ

Key Financial Figures

• $450,000 — ovisions; (ii) order civil penalties of $450,000 against UHP, $240,000 against Beplate,
• $240,000 — ivil penalties of $450,000 against UHP, $240,000 against Beplate, and $225,000 against S
• $225,000 — inst UHP, $240,000 against Beplate, and $225,000 against Schiliro; (iii) impose permanen
• $1,010,976 — and (iv) order Beplate to reimburse UHP $1,010,976.15, representing profits from his sales
• $20,000 — against them, and orders Avis to pay a $20,000 civil penalty. The SEC's investigation

Filing Documents

• ueec_sc13da.htm (SC 13D/A) — 39KB
• 0001477932-24-007836.txt ( ) — 40KB

. Security and Issuer

Item 1 . Security and Issuer This statement relates to the Common Stock of United Health Products, Inc. (the "Issuer"). The Issuer's executive office is located at 520 Fellowship Road, Suite #D-406, Mount Laurel, NJ 08054.

. Identity and Background

Item 2 . Identity and Background (a) Douglas K. Beplate (b) P.O. Box #407, 1777 South Burlington Blvd., Burlington, WA 98233. (c) Retired. (d) Not applicable. (e) See Appendix 1 for SEC Press Release dated June 8, 2022. (f) USA

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration Services rendered.

Purpose of Transactions

Item 4. Purpose of Transactions (a) - (j) Not applicable. The Reporting Person has acquired the securities covered by this schedule as consideration for services rendered to the Issuer. The Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions required to be described in Item 4 of Schedule 13D. CUSIP No. 91059D100 SCHEDULE 13D Page 4 of 5 Pages

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer (a) - (b) As of December 3, 2024, the reporting person beneficially owns 6,700,000 shares of common stock of the issuer, representing 2.68% of the issuer's outstanding shares of common stock. The reporting person has the sole power to dispose and vote of the 6,700,000 shares of Common Stock owned by him. Also excludes 18,000,000 shares of common stock that were contributed by the Reporting Person to an Irrevocable Grantor Trust that he formed in 2022 and which is managed by an independent trustee, and where the Reporting Person is not, and by the Trust terms cannot become, a beneficiary. The Reporting Person therefore disclaims any beneficial ownership. Also excludes 12,307 shares of common stock owned by his spouse for which he disclaims beneficial ownership. (c) - (e) Not Applicable

Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of the Issuer. Not applicable.

Materials to be filed as Exhibits

Item 7. Materials to be filed as Exhibits Not applicable. CUSIP No. 91059D100 SCHEDULE 13D Page 5 of 5 Pages Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: December 3, 2024 Signature By: /s/ Douglas K. Beplate Douglas K. Beplate Appendix 1 United Health Products, Inc., Douglas Beplate, and Louis Schiliro SEC Charges Medical Supply Company and Executives for Accounting Fraud and Suspends Audit Professionals for Improper Professional Conduct Litigation Release No. 25413 / June 8, 2022 Securities and Exchange Commission v. United Health Products, Inc., Douglas Beplate, and Louis Schiliro , No. 1:22-cv-03612 (D.N.J. filed June 8, 2022) The Securities and Exchange Commission today charged medical supply company United Health Products, Inc., its former CEO and Chairman, Douglas Beplate, and its former COO, Louis Schiliro, with allegedly defrauding investors by materially inflating the company's financial results in its 2017 and 2018 SEC filings. The SEC's complaint alleges that Beplate and Schiliro engineered two fraudulent sales transactions that they had UHP record and report in UHP's publicly-filed financial statements. As alleged in the complaint, in the first fraudulent sales transaction, in May 2017, Beplate and Schiliro procured a sham purchase order back-dated to March 2017 from a customer for product that was quickly cancelled and UHP never shipped. In the second allegedly fraudulent sale, Beplate and Schiliro orchestrated a purported December 2017 sale of a large amount of product to a customer who had never ordered it. The complaint alleges that Beplate and Schiliro took measures for UHP to report these fraudulent sales as revenue and receivables in UHP's 2017 and 2018 Forms 10-Q and 10-K, including repeatedly lying to and concealing the true facts from UHP's auditors. The SEC's complaint, filed in the U.S.

View Full Filing

View this SC 13D/A filing on SEC EDGAR